FIELD: medicine； pharmaceuticals.SUBSTANCE: invention relates to a compound of formula Ior a pharmaceutically acceptable salt thereof, where Z isor ,where X is absent, or X is selected from a group consisting of NH and CH2； R is selected from a group consisting of hydrogen, amino and lower alkyl, R1 is selected from a group consisting of hydrogen and halogen, R2 is hydrogen, R3 and R4 are independently selected from a group consisting of hydrogen, C1-C8 alkyl, (CR5R6)aC(O)OR7, (CR5R6)aOR7, (CR5R6)aC(O)N(R7)2, (CR5R6)aN(R7)2, wherein N(R7)2 can be taken together to form 3–7-member heterocyclic ring optionally substituted with one or more R5, wherein, if one of R3 and R4 is (CR5R6)aC(O)OR7, the other can not be (CR5R6)aC(O)OR7； or R3 and R4 can be taken together with a sulfur atom to form 4–7-member heterocyclic ring optionally substituted with one or more R9, R5 is selected from a group consisting of hydrogen, hydroxy and CH2CH2OCH2CH2OH； R6 is hydrogen； R7 is selected from a group consisting of hydrogen, C1-C8 alkyl, fluorine； R9 is selected from a group consisting of hydrogen, C1-C8 alkyl； Ar1 and Ar2 are independently selected from a group consisting of, , , , , ,where R8 is selected from a group consisting of hydrogen, C1-C4 alkyl, amino, hydroxyl, alkoxy, halogen and CF3, and equals 0 or integer from 1 to 4.EFFECT: compounds are able to modulate the tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.19 cl, 10 tbl, 42 exИзобретение относится к соединению формулы Iили его фармацевтически приемлемой соли, где Z представляет собойили ,где X отсутствует, или X выбран из группы, состоящей из NH и CH2； R выбран из группы, состоящей из водорода, амино и низшего алкила, R1 выбран из группы, состоящей из водорода и галогена, R2 представляет собой водород, R3 и R4 независимо выбраны из группы, состоящей из водорода, C1-C8 алкила, (CR5R6)aC(O)OR7, (CR5R6)aOR7, (CR5R6)aC(O)N(R7)2, (CR5R6)aN(R7)2, причем N(R7)2 мог
